Development of antiviral therapy for severe acute respiratory syndrome

doi:10.1016/j.antiviral.2005.03.002

Review

. 2005 Jun;66(2-3):81-97.

doi: 10.1016/j.antiviral.2005.03.002. Epub 2005 Apr 26.

Development of antiviral therapy for severe acute respiratory syndrome

Jindrich Cinatl Jr¹, Martin Michaelis, Gerold Hoever, Wolfgang Preiser, Hans Wilhelm Doerr

Affiliations

Affiliation

¹ Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. Cinatl@em.uni-frankfurt.de

PMID: 15878786
PMCID: PMC7132397
DOI: 10.1016/j.antiviral.2005.03.002

Review

Development of antiviral therapy for severe acute respiratory syndrome

Jindrich Cinatl Jr et al. Antiviral Res. 2005 Jun.

. 2005 Jun;66(2-3):81-97.

doi: 10.1016/j.antiviral.2005.03.002. Epub 2005 Apr 26.

Authors

Jindrich Cinatl Jr¹, Martin Michaelis, Gerold Hoever, Wolfgang Preiser, Hans Wilhelm Doerr

Affiliation

¹ Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. Cinatl@em.uni-frankfurt.de

PMID: 15878786
PMCID: PMC7132397
DOI: 10.1016/j.antiviral.2005.03.002

Abstract

A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.

PubMed Disclaimer

Cited by

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
Santos IA, Grosche VR, Bergamini FRG, Sabino-Silva R, Jardim ACG. Santos IA, et al. Front Microbiol. 2020 Aug 13;11:1818. doi: 10.3389/fmicb.2020.01818. eCollection 2020. Front Microbiol. 2020. PMID: 32903349 Free PMC article. Review.
Recent Advances in Antiviral Activities of Triterpenoids.
Liu Y, Yang L, Wang H, Xiong Y. Liu Y, et al. Pharmaceuticals (Basel). 2022 Sep 21;15(10):1169. doi: 10.3390/ph15101169. Pharmaceuticals (Basel). 2022. PMID: 36297280 Free PMC article. Review.
Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.
Yeung KS, Yamanaka GA, Meanwell NA. Yeung KS, et al. Med Res Rev. 2006 Jul;26(4):414-33. doi: 10.1002/med.20055. Med Res Rev. 2006. PMID: 16521129 Free PMC article. Review.
Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression.
Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW, Cinatl J Jr. Michaelis M, et al. PLoS One. 2011;6(5):e19705. doi: 10.1371/journal.pone.0019705. Epub 2011 May 17. PLoS One. 2011. PMID: 21611183 Free PMC article.
Antiviral applications of RNAi for coronavirus.
Wu CJ, Chan YL. Wu CJ, et al. Expert Opin Investig Drugs. 2006 Feb;15(2):89-97. doi: 10.1517/13543784.15.2.89. Expert Opin Investig Drugs. 2006. PMID: 16433589 Free PMC article. Review.

See all "Cited by" articles

References

1. Adler H., Beland J.L., Del-Pan N.C., Kobzik L., Brewer J.P., Martin T.R., Rimm I.J. Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2) J. Exp. Med. 1997;185:1533–1540. - PMC - PubMed
1. Akaike T., Noguchi Y., Ijiri S., Setoguchi K., Suga M., Zheng Y.M., Dietzschold B., Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. U.S.A. 1996;93:2448–2453. - PMC - PubMed
1. Akerstrom S., Mousavi-Jazi M., Klingstrom J., Leijon M., Lundkvist A., Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J. Virol. 2005;79:1966–1969. - PMC - PubMed
1. Ali M.B. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med. J. 2003;9:391–392. - PubMed
1. Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

[1] Adler H., Beland J.L., Del-Pan N.C., Kobzik L., Brewer J.P., Martin T.R., Rimm I.J. Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2) J. Exp. Med. 1997;185:1533–1540. - PMC - PubMed

[2] Adler H., Beland J.L., Del-Pan N.C., Kobzik L., Brewer J.P., Martin T.R., Rimm I.J. Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2) J. Exp. Med. 1997;185:1533–1540. - PMC - PubMed

[3] Akaike T., Noguchi Y., Ijiri S., Setoguchi K., Suga M., Zheng Y.M., Dietzschold B., Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. U.S.A. 1996;93:2448–2453. - PMC - PubMed

[4] Akaike T., Noguchi Y., Ijiri S., Setoguchi K., Suga M., Zheng Y.M., Dietzschold B., Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. U.S.A. 1996;93:2448–2453. - PMC - PubMed

[5] Akerstrom S., Mousavi-Jazi M., Klingstrom J., Leijon M., Lundkvist A., Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J. Virol. 2005;79:1966–1969. - PMC - PubMed

[6] Akerstrom S., Mousavi-Jazi M., Klingstrom J., Leijon M., Lundkvist A., Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J. Virol. 2005;79:1966–1969. - PMC - PubMed

[7] Ali M.B. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med. J. 2003;9:391–392. - PubMed

[8] Ali M.B. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med. J. 2003;9:391–392. - PubMed

[9] Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. - PubMed

[10] Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Development of antiviral therapy for severe acute respiratory syndrome

Affiliation

Development of antiviral therapy for severe acute respiratory syndrome

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous